Q1FY27 results: revenue up 28%, PAT up 27%; board approves Rs 368 Cr capex
HSCL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.9 pts more than Nifty Smallcap 250 and 6.0 pts more than its Chemicals & Petrochemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Himadri Speciality Chemical reported Q1FY27 consolidated revenue from operations at Rs 1,431.88 Cr (up 28% YoY from Rs 1,118.29 Cr) and PAT at Rs 228.43 Cr (up 27% YoY from Rs 179.36 Cr). Board approved three capex plans totaling Rs 368 Cr funded via internal accruals: Rs 128 Cr to expand Anthraquinone and Carbazole capacity to 5300 MTPA, Rs 70 Cr for India's first Carbon Nano Tubes facility in West Bengal, and Rs 170 Cr for Super Speciality Carbon Black. Auditors Singhi & Co issued an unqualified limited review report.
Strong Q1 results confirm growth momentum. Major capex in high-value specialty products signals future revenue diversification and capacity expansion.